Research programme: HIV attachment inhibitors - Bristol-Myers SquibbAlternative Names: Research programme: HIV attachment inhibitors - Bristol-Myers Squibb/Evotec
Latest Information Update: 15 Jul 2015
At a glance
- Originator Bristol-Myers Squibb
- Class Indoles
- Mechanism of Action Virus attachment inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 16 Sep 2014 No development reported - Preclinical for HIV infections in USA (PO)